Status:
RECRUITING
The Development, Safety, and Feasibility of an Artificial Intelligence-Powered Platform (NodeAI) for Real-Time Prediction of Mediastinal Lymph Node Malignancy During Endobronchial Ultrasound Staging for Lung Cancer
Lead Sponsor:
St. Joseph's Healthcare Hamilton
Conditions:
Lung Cancer
Non Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Lung cancer is the leading cause of annual cancer deaths globally, more than breast, prostate, and colon cancers combined. The staging of chest lymph nodes (LNs) is a crucial step in the lung cancer d...
Eligibility Criteria
Inclusion
- Patients ≥ 18 years of age diagnosed with suspected or confirmed NSCLC based on CT and PET scans that are referred for chest staging by EBUS-TBNA
- CT and PET scans completed
Exclusion
- Patients with cN0 disease AND peripheral tumors AND tumors \< 2 cm in diameter (those do not require chest staging)
Key Trial Info
Start Date :
January 10 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT06540196
Start Date
January 10 2025
End Date
December 31 2026
Last Update
June 12 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
St. Joseph's Healthcare Hamilton / McMaster University
Hamilton, Ontario, Canada, L8N 4A6